New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2015 and is headquartered in Hangzhou, China.
Frequently asked questions
What sector does New Horizon Health Ltd (6606) operate in?
New Horizon Health Ltd belongs to the Healthcare sector and operates in the Medical Devices industry.
What is New Horizon Health Ltd (6606) current stock price?
As of the latest data, New Horizon Health Ltd stock price is HK$14.14, with a previous close of HK$14.14.
What is New Horizon Health Ltd (6606) current market capitalization?
New Horizon Health Ltd market cap is approximately 6.34 billion.
Does New Horizon Health Ltd (6606) pay dividends?
No. New Horizon Health Ltd does not pay a dividend.
What is New Horizon Health Ltd (6606) beta (volatility) score?
New Horizon Health Ltd has a beta of 1.263, suggesting it is more volatile than the market.
